Comparative thermodynamic analysis in solution of a next generation antibody mimetic to VEGF

Article


Khalili, H., Brocchini, Steve, Khaw, Peng Tee and Filippov, Sergey K. 2018. Comparative thermodynamic analysis in solution of a next generation antibody mimetic to VEGF. RSC Advances. 8 (62), pp. 35787-35793.
AuthorsKhalili, H., Brocchini, Steve, Khaw, Peng Tee and Filippov, Sergey K.
Abstract

An antibody mimetic known as Fab–PEG–Fab (FpF) is a stable bivalent molecule that may have some potential therapeutic advantages over IgG antibodies due to differences in their binding kinetics as determined by surface plasmon resonance. Here we describe the thermodynamic binding properties to vascular endothelial growth factor (VEGF) of the FpF antibody mimetics derived from bevacizumab and ranibizumab. Bevacizumab is an IgG antibody and ranibizumab is an antibody fragment (Fab). Both are used clinically to target VEGF to inhibit angiogenesis. FpFbeva displayed comparable binding affinity (KD) and binding thermodynamics (ΔH = −25.7 kcal mole−1 and ΔS = 14 kcal mole−1) to bevacizumab (ΔH = −25 kcal mole−1, ΔS = 13.3 kcal mole−1). FpFrani interactions with VEGF were characterised by large favourable enthalpy (ΔH = −42 kcal mole−1) and unfavourable entropy (ΔS = 31 kcal mole−1) changes compared to ranibizumab (ΔH = −18.5 kcal mole−1 and ΔS = 6.7 kcal mole−1), which being a Fab, is mono-valent. A large negative entropy change resulting in binding of bivalent FpF to homodimer VEGF might be due to the conformational change of the flexible regions of the FpF upon ligand binding. Mono-valent Fab (i.e. ranibizumab or the Fab derived from bevacizumab) displayed a larger degree of freedom (smaller unfavourable entropy) upon binding to homodimer VEGF. Our report describes the first comprehensive enthalpy and entropy compensation analysis for FpF antibody mimetics. While the FpFs displayed similar thermodynamics and binding affinity to the full IgG (i.e. bevacizumab), their enhanced protein stability, slower dissociation rate and lack of Fc effector functions could make FpF a potential next-generation therapy for local tissue-targeted indications.

JournalRSC Advances
Journal citation8 (62), pp. 35787-35793
ISSN2046-2069
Year2018
PublisherRoyal Society of Chemistry
Publisher's version
License
Digital Object Identifier (DOI)doi:10.1039/C8RA07059H
Web address (URL)https://doi.org/10.1039/C8RA07059H
Publication dates
Online19 Oct 2018
Publication process dates
Deposited22 Oct 2018
Accepted12 Oct 2018
Accepted12 Oct 2018
FunderUniversity of East London
National Institute for Health Research
Moorfields Eye Charity
Helen Hamlyn Trust in memory of Paul Hamlyn
The Michael and Isle Katz Foundation
Czech Science Foundation GACR
University of East London
National Institute for Health Research
Moorfields Eye Charity
Helen Hamlyn Trust in memory of Paul Hamlyn
The Michael and Isle Katz Foundation
Czech Science Foundation GACR
Copyright information© 2018 The authors
LicenseCC BY 4.0
Permalink -

https://repository.uel.ac.uk/item/8462z

  • 12
    total views
  • 50
    total downloads
  • 5
    views this month
  • 5
    downloads this month

Related outputs

Storage Stability Studies of Anti-VEGF FpF Antibody Mimetics
Khalili, H., Brocchini, Steve, Khaw, Peng Tee and Filippov, Sergey 2016. Storage Stability Studies of Anti-VEGF FpF Antibody Mimetics. 2016 AAPS Annual Meeting and Exposition. Denver, Co, USA 13 - 17 Nov 2016 American Association of Pharmaceutical Scientists.
An anti-TNF--α antibody mimetic to treat ocular inflammation
Khalili, H., Lee, Richard W., Khaw, Peng Tee, Brocchini, Steve, Dick, Andrew D. and Copland, David A. 2016. An anti-TNF--α antibody mimetic to treat ocular inflammation. Scientific Reports. 6 (36905).
Fc-fusion mimetics
Khalili, H., Khaw, P. T. and Brocchini, S. 2016. Fc-fusion mimetics. Biomaterials Science. 4 (6), pp. 943-947.
Storage stability of bevacizumab in polycarbonate and polypropylene syringes
Khalili, H., Sharma, Garima, Froome, Andrew, Khaw, Peng Tee and Brocchini, Steve 2015. Storage stability of bevacizumab in polycarbonate and polypropylene syringes. Eye. 29 (6), pp. 820-827.